Skip to main content

Table 3 Relationship between CRP reduction and ACR response following ACZ885 treatment

From: The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Group CRP reduction at day 43 versus baseline ACR response at day 43
   <20% 20% to <50% 50% or more
10 mg/kg ACZ885 <20% 4 0 0
  20 to <50% 0 1 1
  50% or more 8 2 2
Placebo <20% 9 1 0
  20 – <50% 2 0 0
  50% or more 3 0 0
  1. Relationship between C-reactive protein (CRP) reduction and American College of Rheumatology (ACR) response at day 43 for patients in the 10 mg/kg group and patients receiving placebo. Note that two subjects are excluded from the 10 mg/kg ACZ885 because of missing data.